SKYE earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -0.44. Updated 2026-07-23.
Skye Bioscience (SKYE) Research Hub
Skye Bioscience (SKYE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.04 USD (-8.52%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.44, market cap 0.02B. This hub links to the full technical, earnings and options research available for SKYE.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.04 USD (-8.52%) |
| 52-week range | 1.64 USD – 6.5 USD |
| Trend regime | Range |
| 14-day RSI | 18.8 (Oversold) |
| Trailing P/E | -0.44 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for SKYE
Covered Call on SKYE: how it works, illustrative setup around the real 2.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SKYE: how it works, illustrative setup around the real 2.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SKYE: how it works, illustrative setup around the real 2.04 USD price, max profit/loss, breakeven and when to use it. Educational.
SKYE technical analysis: range, last 2.04 USD, RSI 18.8, 52w range 1.64 USD–6.5 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SKYE in?
Skye Bioscience (SKYE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SKYE in an uptrend or downtrend?
As of 2026-09-11, SKYE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SKYE's trailing P/E ratio?
SKYE's trailing P/E is -0.44, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does SKYE next report earnings?
SKYE is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.29 USD.